Loading...
Market
Will a peer-reviewed study confirm Ozempic's Alzheimer's risk reduction by October 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Publication in major scientific journals such as The Lancet or JAMA
Story
Ozempic Linked to 70% Lower Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 12:14 PM
Novo Nordisk's diabetes drug Ozempic, which contains the active ingredient semaglutide, has been linked to a significantly reduced risk of being diagnosed with Alzheimer's disease among people with type 2 diabetes. The observational study found a 70% lower risk of Alzheimer's diagnosis compared to other diabetes medications, based on an analysis of medical records. This adds to the growing evidence of Ozempic's effects beyond type 2 diabetes and obesity, indicating potential benefits in neurodegenerative diseases. Wegovy, another drug containing semaglutide, may also reduce Alzheimer's risk.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Confirms link • 25%
Refutes link • 25%
Inconclusive • 25%
No publication • 25%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Yes • 50%
No • 50%
